China health care companies received a significant reprieve in terms of geopolitical risks when the US Senate declined to ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Air pollution was cited as a key driver of this type of lung cancer, with the highest levels reported in East Asia, particularly China, the release stated. Worldwide, adenocarcinoma made up more ...

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows ...

In a trailblazing fusion of immunology and ingenuity, a team of Chinese researchers ... ovarian and lung – achieved halted tumour growth or shrinkage, with one cervical cancer patient declared ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...

One key subtype of lung cancer – adenocarcinoma – has become predominant among women in 185 countries, the authors wrote in the Chinese-funded study. “Air pollution can be considered an ...

Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

The current patterns of cancer incidence and mortality in southeast Asia are primarily driven by breast cancer in women and ...